Preventing NLRP3 inflammasome activation: Therapeutic atrategy and challenges in atopic dermatitis
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2024.113696 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Yiran Sun und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Chengdu Medical College, Chengdu 610500, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 167 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Shanxi Provincial Science and Technology Department.
Abstract (Originalsprache)
Atopic dermatitis (AD) is a prevalent inflammatory skin disorder characterized by its chronic, persistent, and recurrent nature. The pathophysiology of this condition is complex, involving various factors including cell-mediated immune responses, compromised skin barrier function, and alterations in hypersensitivity reactions. These components synergistically contribute to the perpetuation of the bothersome "itch-scratch-itch" cycle. Recent research has highlighted the significant role of the NLRP3 inflammasome in the development of AD and other inflammatory conditions. Current research indicates that the NLRP3 inflammasome plays a pivotal role in both the acute and chronic phases of AD by modulating the Th2/Th1 immune deviation. Moreover, the pharmacological suppression of NLRP3 has shown promising results in mitigating the pathological aspects of AD. This review outlines potential drug development strategies that target the NLRP3 inflammasome as a therapeutic approach for AD and the challenges faced in this endeavor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Chengdu Medical College, Chengdu 610500, China.
- School of Clinical Medicine, Chengdu Medical College, Chengdu 610500, China.
- Department of R&D, Keystonecare Technology (Chengdu) Co., Ltd, Chengdu 610094, China.
- School of Biosciences and Technology, Key Laboratory of Target Discovery and Protein Drug Development in Major Diseases at Chengdu Medical College of Sichuan Province, Chengdu Medical College, Chengdu 610500, China.
- College of Life Sciences, Sichuan Normal University, Chengdu 610101, China.
- Department of Dermatology and Venereology, Nanbu County People's Hospital, Nanchong 637399, China.
Förderung
- China Postdoctoral Science Foundation
- Shanxi Provincial Science and Technology Department
Zitieren
APA
Sun, Y., Zhou, Y., Peng, T., Huang, Y., Lu, H., Ying, X., Kang, M., Jiang, H., Wang, J., Zheng, J., Zeng, C., Liu, W., Zhang, X., Ai, L., & Peng, Q. (2025). Preventing NLRP3 inflammasome activation: Therapeutic atrategy and challenges in atopic dermatitis. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113696
Vancouver
Sun Y, Zhou Y, Peng T, Huang Y, Lu H, Ying X, et al. Preventing NLRP3 inflammasome activation: Therapeutic atrategy and challenges in atopic dermatitis. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2024.113696
BibTeX
@article{Sun2025,
author = {Sun, Yiran and Zhou, Yangang and Peng, Tong and Huang, Yuhang and Lu, Hao and Ying, Xiran and Kang, Mingsheng and Jiang, Hao and Wang, Jingying and Zheng, Jiayao and Zeng, Chenyu and Liu, Wanting and Zhang, Xiaoyu and Ai, Lin and Peng, Quekun},
title = {Preventing NLRP3 inflammasome activation: Therapeutic atrategy and challenges in atopic dermatitis},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2024.113696}
}
EUVIMED